OPTIMA

A Study to Assess Safety, Tolerability and Efficacy of Garetosmab Versus Placebo Administered Intravenously (IV) in Adult Participants With Fibrodysplasia Ossificans Progressiva (FOP)

GaretosmabOngoingActive not recruitingPhase 3Open NCT05394116 on ClinicalTrials.gov ↗

Population

Loading…

Intervention

Loading…

Comparator

Loading…

Loading…

OPTIMA · Trial Tracker · ComplyRx